🇺🇸 FDA
Patent

US 12371442

Isoindolinone and indazole compounds for the degradation of EGFR

granted A61KA61K31/427A61K31/496

Quick answer

US patent 12371442 (Isoindolinone and indazole compounds for the degradation of EGFR) held by C4 THERAPEUTICS, INC. expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
C4 THERAPEUTICS, INC.
Grant date
Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/427, A61K31/496, A61K31/506, A61K31/5377